Find a trial

At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.


Use the search function below to find a clinical trial that may suit you and your cancer diagnosis

- Advanced

LOXO-FRA-24001 / J5E-OX-JZXA

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-A317-26808-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-24714-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LOXO-ENC-23001 / J5A-OX-JZWA

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

DM005001

A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

VVD-130850-01

A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ARC-20

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LUNA / CP-MGC026-01

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Locations

Adelaide (Kurralta Park), Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AWT020-001

A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

IL Believe

A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Locations

Farrer Park

Diagnosis

Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma

Open for recruitment
View Trial

BBI-TP-3654-102

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Locations

Adelaide (Windsor Gardens)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

DB-1303-O-1001

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-A317-A3055-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AK127-101

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

STARSTRUCK / 177Lu-TLX250-001

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HMDB-001-002

A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ZN-c3-004

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Locations

Chermside

Diagnosis

Endometrial cancer

Trial on hold
View Trial

ZN-c3-005

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)

Locations

Chermside

Diagnosis

Ovarian cancer

Trial on hold
View Trial

BA3011-002

A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor

Locations

Central Building (Oncology)

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASPEN-06 / AT148006

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

Southport

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

REFRaME-01 / STRO-002-GM3

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

OLYMPIA-3 / R1979-ONC-2105

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Locations

Wesley

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

OLYMPIA-1 / R1979-HM-2298

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Locations

Wesley

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

Viktoria-1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

X4P-001-110

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Locations

Southport

Open for recruitment
View Trial

DeLLphi-306

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Locations

Mount Alvernia

Diagnosis

Lung cancer

Open for recruitment
View Trial

RAMP 301 / VS-6766-301

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

XPORT-EC-042

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Locations

Southport

Diagnosis

Endometrial cancer

Open for recruitment
View Trial

CS5001-101

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours, Lymphoma – B-cell Non Hodgkin’s, Lymphoma – T-Cell Non Hodgkin’s, Lymphoma – Hodgkin’s

Open for recruitment
View Trial

DM001001

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

SCTB14-X101

A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CAPTURE / BCT1901

A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

BNT327-02

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

pionERA Breast Cancer

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Locations

Gleneagles, Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

pionERA

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Locations

Gleneagles, Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

INAVO122

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

CAMBRIA-1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

SB221

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer

Locations

Adelaide (Kurralta Park)

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

Duravelo-2 / BT8009-230

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Locations

Wesley

Diagnosis

Urothelial cancer

Open for recruitment
View Trial

STELLAR 303

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

STELLAR-304 / XL094-304

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Locations

Chermside

Diagnosis

Cancer-unknown origin

Open for recruitment
View Trial

EvoPAR-Prostate01 / D9723C00001

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Locations

Townsville, Chermside, Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASPIRE / CL-SBP-101-04

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Pancreatic cancer

Trial on hold
View Trial

BGB-A317-LBL-007-201

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Locations

South Brisbane

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

Relativity-106

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

Locations

Farrer Park

Diagnosis

Liver cancer

Open for recruitment
View Trial

C4391022

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Locations

Townsville

Diagnosis

Breast cancer

Open for recruitment
View Trial

AMLM22/D1

AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Leukaemia

Open for recruitment
View Trial

REGENERON_ R1979-ONC-1625

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma

Locations

Farrer Park

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

BGB-3111-LTE1

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Locations

Wesley

Diagnosis

B-cell malignancies

Open for recruitment
View Trial

SGNDV-001

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)

Locations

Chermside

Diagnosis

Urothelial cancer

Open for recruitment
View Trial

LINKER-MM3 / R5458-ONC-2245

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

Locations

Wesley

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

CLINCH / ATG-022-ST-001

An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ALLG NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

BRIGHTLINE-2 / 1403-0011

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LIBERATE

Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)

Locations

Epworth Richmond, Epworth Freemasons, Geelong

Diagnosis

Prostate cancer

Open for recruitment
View Trial

DECREASE / TROG 19.06

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Locations

Epworth Richmond

Diagnosis

Prostate cancer

Open for recruitment
View Trial

EXPERT / BCT1601

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

Locations

Epworth Richmond

Diagnosis

Breast cancer

Open for recruitment
View Trial

ERUPT

External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)

Locations

Toowoomba

Diagnosis

Prostate cancer

Open for recruitment
View Trial

AMT-116-01

First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AMT-151-01

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AMT-253-01

First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HERTHENA-PanTumor01 / U31402-277

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Locations

Chermside, Hobart

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

I-MAT / MASC 03.18

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Locations

Hobart

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

Lunar-2

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Locations

Farrer Park, Mount Alvernia

Diagnosis

Lung cancer

Open for recruitment
View Trial

MASTERPLAN

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease

Locations

Gold Coast University Hospital

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

MRDR

Myeloma and Related Disease Registry

Locations

Wesley, South Brisbane, Chermside, Southport

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

OPTIMA / BCT 2202

Optimal personalised treatment of early breast cancer using multiparameter analysis

Locations

Southport, Wesley, Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Breast cancer

Open for recruitment
View Trial

SLN124-004

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

HARMONY / R3767-ONC-2011

Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Locations

Hobart

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

VIKTORIA-1 / CELC-G-301

Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

Locations

Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

JSKN033-101

Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumours

Locations

Wesley

Diagnosis

Advanced solid tumours

Trial on hold
View Trial

ANZadapt

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

Locations

Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

PRIME_LUNG

PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer. A Pilot Study

Locations

Gold Coast University Hospital

Diagnosis

Lung cancer

Open for recruitment
View Trial

FIG / TROG 18.06

Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)

Locations

Wesley

Diagnosis

Brain cancer

Open for recruitment
View Trial

TREMOR

Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)

Locations

Epworth Richmond

Diagnosis

Neurological conditions

Open for recruitment
View Trial

KEYVIBE-006 / MK-7684A-006

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

SUNRAY-01 / J3M-MC-JZQB

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

Q-IMPROvE

The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

ROSEND

The ROSEND Trial – A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatment

Locations

Revesby, Wahroonga, Gosford

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

ABCPro

Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.

Locations

Bowen Icon Cancer Centre

Diagnosis

Breast cancer

Open for recruitment
View Trial

TRACIE / CO-AU-979-6695

TRodelvy use in AdvanCed TrIple Negative BrEast Cancer in Australia

Locations

Adelaide (Kurralta Park), Adelaide (Windsor Gardens), Townsville, Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

TUGETHER / BCT2102

Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial
There are no clinical trials currently available

We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.

Search

Contact us
Become a patient